Document is current

Any future updates will be listed below

Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated

Crossref DOI link: https://doi.org/10.1007/s12072-023-10611-z

Published Online: 2023-11-09

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark